Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

Valneva SENASDAQ: VALN

Deferred Income Tax · Q1 FY2026 · quarter ended Mar 2026

Deferred income tax outflow grows to €0

Q1 FY2026 deferred income tax was €0, compared with €0 a year earlier. Trailing-twelve-month deferred income tax was €752.25K.

Context

  • Deferred income tax amounted to 0.6% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Deferred income tax increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly deferred income tax holds near €0 or moves back toward the trailing-twelve-month quarterly average of €188.06K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0-100.0% QoQ
Last fiscal yearDec 2025
€1.07M+41.0% YoY
LTMMar 2026
€752.25K— YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+41.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

EUR · from the cash flow

Latest · FY2025
1.07M EUR
Year-over-year change
+41.0%
4-year CAGR
-25.3%

Deferred Income Tax vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred income tax is compared through growth and share of revenue rather than absolute size.
  • Deferred income tax amounts to 0.5% of revenue for VALN, versus a peer median of 0.0%.
VALN Competitors
Deferred Income Tax for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VALNValneva SELTM Mar 2026€752.25K EUR——0.5%
MRNAModerna, Inc.LTM Sep 2026$0 USD——0.0%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
IBRXImmunityBio, Inc.LTM Sep 2026$0 USD——0.0%
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
NVAXNovavax, Inc.LTM Mar 2026$0 USD——0.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 USD——0.0%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
Peer median (excluding VALN) —+100.0%—0.0%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
Deferred Income Tax3.45M(1.54M)2.8M761K1.07M
Stock-Based Compensation14.51M(8.66M)5.11M7.98M9.53M
Change in Working Capital36.13M(145.98M)(145.06M)(11.57M)(148K)
Accounts Receivables(21.35M)12.4M(2.86M)15.71M13.33M
Inventory(92.37M)84.22M(9.17M)(6.8M)1.03M
Accounts Payables35.24M(14.05M)(17.4M)00
Other Working Capital114.61M(228.55M)(115.65M)(20.48M)(14.51M)
Other Non-Cash Items81.96M33.07M18.25M(71.72M)30.09M
Operating Cash Flow76.9M(245.34M)(202.74M)(67.22M)(52.89M)
Capital Expenditures(93.17M)(29.32M)(14.31M)(16.44M)(4.48M)
Acquisitions (Net)08K(10.95M)00
Purchases of Investments00000
Sales of Investments0000841K
Other Investing Activities55K260K4.6M90.78M1.87M
Investing Cash Flow(93.12M)(29.05M)(20.59M)76.92M(1.71M)
Debt Repayment(3.9M)34.49M75.89M(6.49M)61K
Common Stock Issued166.82M189.84M0030M
Common Stock Repurchased00(240K)00
Dividends Paid00000
Other Financing Activities(8.42M)(9.21M)(12.57M)(19.97M)(30.69M)
Financing Cash Flow154.5M215.12M63.08M30.68M(621K)
Effect of Forex Changes3.96M(828K)(204K)1.81M(3.4M)
Net Change in Cash142.29M(57.21M)(160.45M)42.19M(58.62M)
Free Cash Flow(16.27M)(274.67M)(217.06M)(83.66M)(57.38M)

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.